CA1151488A - Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier - Google Patents

Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier

Info

Publication number: CA1151488A
Authority: CA; Canada
Prior art keywords: blood; fiber; spindle; fibers; housing
Prior art date: 1980-09-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000359464A

Other languages

English (en)

Inventor

Thomas A. Davis

Lee R. Beck

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Stolle Research and Development Corp

Original Assignee

Stolle Research and Development Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-09-03

Filing date

1980-09-03

Publication date

1983-08-09

1980-09-03 Application filed by Stolle Research and Development Corp filed Critical Stolle Research and Development Corp

1980-09-03 Priority to CA000359464A priority Critical patent/CA1151488A/fr

1983-08-09 Application granted granted Critical

1983-08-09 Publication of CA1151488A publication Critical patent/CA1151488A/fr

Status Expired legal-status Critical Current

Links

210000004369 blood Anatomy 0.000 title claims abstract description 36
239000008280 blood Substances 0.000 title claims abstract description 36
230000001951 hemoperfusion Effects 0.000 title claims abstract description 22
230000004048 modification Effects 0.000 title abstract description 5
238000012986 modification Methods 0.000 title abstract description 5
239000000835 fiber Substances 0.000 claims abstract description 69
239000012636 effector Substances 0.000 claims abstract description 12
239000013060 biological fluid Substances 0.000 claims description 8
239000000463 material Substances 0.000 claims description 8
230000000694 effects Effects 0.000 claims description 7
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
238000004891 communication Methods 0.000 claims description 2
239000012530 fluid Substances 0.000 description 13
230000006378 damage Effects 0.000 description 10
239000000306 component Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
239000004033 plastic Substances 0.000 description 6
229920003023 plastic Polymers 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
238000000034 method Methods 0.000 description 5
230000004075 alteration Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
-1 such aspolyamides Polymers 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
239000003463 adsorbent Substances 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
230000003292 diminished effect Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
230000037452 priming Effects 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
108010093096 Immobilized Enzymes Proteins 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012503 blood component Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000013626 chemical specie Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
229920003043 Cellulose fiber Polymers 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
208000003870 Drug Overdose Diseases 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
102220517925 Humanin_S14P_mutation Human genes 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
102000005717 Myeloma Proteins Human genes 0.000 description 1
108010045503 Myeloma Proteins Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000032976 Neuroendocrine carcinoma of pancreas Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033296 Overdoses Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108010092464 Urate Oxidase Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000002965 anti-thrombogenic effect Effects 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229960000182 blood factors Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000005465 channeling Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960001091 chenodeoxycholic acid Drugs 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000002844 continuous effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000725 drug overdose Toxicity 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
230000004907 flux Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
239000013628 high molecular weight specie Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000012784 inorganic fiber Substances 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
210000001853 liver microsome Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000013627 low molecular weight specie Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940079938 nitrocellulose Drugs 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000011368 organic material Substances 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001195 polyisoprene Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002296 pyrolytic carbon Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000004804 winding Methods 0.000 description 1

Landscapes

External Artificial Organs (AREA)

CA000359464A 1980-09-03 1980-09-03 Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier Expired CA1151488A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000359464A CA1151488A (fr)	1980-09-03	1980-09-03	Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000359464A CA1151488A (fr)	1980-09-03	1980-09-03	Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier

Publications (1)

Publication Number	Publication Date
CA1151488A true CA1151488A (fr)	1983-08-09

Family

ID=4117794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000359464A Expired CA1151488A (fr)	1980-09-03	1980-09-03	Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier

Country Status (1)

Country	Link
CA (1)	CA1151488A (fr)

1980
- 1980-09-03 CA CA000359464A patent/CA1151488A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-08-09	MKEX	Expiry

Publication	Publication Date	Title
US4252653A (en)	1981-02-24	Hemoperfusion device for specific modification or removal of components of whole blood
AU729964B2 (en)	2001-02-15	Affinity membrane system and method of using same
US4787974A (en)	1988-11-29	Blood purification
US5211850A (en)	1993-05-18	Plasma filter sorbent system for removal of components from blood
US4836928A (en)	1989-06-06	Separation method, separation device and separation apparatus for separating body fluid into respective components
US4714556A (en)	1987-12-22	Blood purification
US6497675B1 (en)	2002-12-24	Device for extracorporeal treatment of physiological fluids of organism
KR101036995B1 (ko)	2011-05-25	중합체 친화성 기질과 이의 제조 방법 및 용도
US5855782A (en)	1999-01-05	Arrangement for removing substances from liquids, in particular blood
EP0166325A2 (fr)	1986-01-02	Procédé et appareil pour la séparation sélective des éléments pathologiques et/ou toxiques du sang ou du plasma par l'utilisation de filtres en forme de bougie
EP0056977B1 (fr)	1985-05-02	Adsorbant pour anticorps et complexes d'immunisation, dispositif d'adsorption et appareil de purification du sang
EP0341413B2 (fr)	2000-05-17	Module et appareil d'adsorption pour le traitement du sang total
JP2004516896A (ja)	2004-06-10	細胞外体液からの特異的生体高分子物質の体外捕獲
US6090292A (en)	2000-07-18	Device for purifying solutions containing proteins and use of the device
EP1110602B1 (fr)	2009-04-15	Matieres servant a eliminer des cannabinoides et colonnes utiles pour eliminer des cannabinoides a l'aide de ces matieres
Weber et al.	1994	The Microspheres based Detoxification System (MDS): A new extracorporeal blood purification technology based on recirculated microspherical adsorbent particles
EP0046470B1 (fr)	1984-12-05	Dispositif à hémoperfusion pour la modification spécifique ou l'élimination des composants du sang
CA1151488A (fr)	1983-08-09	Dispositif d'hemoperfusion pour la modification ou l'extraction de facteurs du sang entier
EP1010428A2 (fr)	2000-06-21	Dispositif d'adsorption et agent adsorbant utilise dans le traitement des humeurs
EP0352917B1 (fr)	1994-04-27	Elimination sélective d'espèces chimiques d'un fluide
FI71486C (fi)	1987-01-19	Hemoperfusionsanordning foer specifik avlaegsning av biologiska komponenter fraon blodet som perfuseras genom anordningen.
EP0350252B1 (fr)	1994-03-23	Espacement d'éléments définissant un passage pour un débit de fluide
WO1991010492A1 (fr)	1991-07-25	Appareil et procede de separation par affinite
NO151808B (no)	1985-03-04	Hemoperfusjonsanordning
JPS6353826B2 (fr)	1988-10-25